0.30Open0.30Pre Close0 Volume66 Open Interest20.00Strike Price0.00Turnover0.00%IV128.60%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma29.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
GH Research Stock Discussion
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
GHRS
Share
• Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8
• Primary endpoint met in phase 2a POC t...
• $ACADIA Pharmaceuticals (ACAD.US)$ : Jefferies Upgrades to Buy from Hold - PT $25 (from $22)
• $Arthur J. Gallagher (AJG.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $185 (from $182)
• $Apple Hospitality REIT Inc (APLE.US)$ : B.Riley Upgrades to Buy from Neutral - PT $19
• $AutoZone (AZO.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $2,420 (from $2,125)
• $Boeing (BA.US)$ : Citigroup Upgr...
No comment yet